The present disclosure relates to an alternative intervention to improve
skeletal muscle health in chronic
kidney disease (CKD). CKD causes
skeletal muscle complications that lead to
increased risk of falls, hospitalizations and mortality. While exercise is a common treatment for these impairments in the general
population, in patients with CKD exercise has shown only marginal improvements in
aerobic capacity and inconsistent effects on
muscle strength,
walking distance, and timed-up-and-go tests indicating this ‘usual’ treatment is not enough in patients in CKD. The present disclosure relates to methods of using an aminoindazole to treat
inflammation and metabolic derangements and to improve
skeletal muscle health in CKD.